Tamara Vokes
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1841353364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $104,094 of the $138,863 with a category attached, or 75.0%. Ascendis Pharma Endocrinology Inc accounts for 77.5% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $87,166, 4.8 times the $18,308 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $1186.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$108K
- Radius Health, Inc.$11K
- Shire North American Group Inc$11K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Chugai Pharmaceutical Co., Ltd.$931
- Vertex$930
- plus $282 from 2 others
Across 81 payments — averaging $3830.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$183K
- Ascendis Pharma Endocrinology Inc$47K
- Chugai Pharmaceutical Co., Ltd.$42K
- Shire North American Group Inc$31K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
What the payments were for
- Consulting fees$17,76413%
- Speaking & faculty fees$104,09475%
- Travel & lodging$14,74211%
- Food & beverage$2,2432%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 76 | $107,566 |
| Radius Health, Inc. | 15 | $11,442 |
| Shire North American Group Inc | 12 | $11,251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $6,460 |
| Chugai Pharmaceutical Co., Ltd. | 4 | $931 |
| Vertex | 2 | $930 |
| Amgen | 2 | $175 |
| Ultragenyx Pharmaceutical Inc. | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yorvipath$84,948
- NATPARA (PARATHYROID HORMONE)$15,958
- Tymlos$11,325
- Non-Covered Product$931
- CRYSVITA$108
How this compares
$138,863 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
- Hong LeeChicago$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.